Medulloblastoma in adults: evaluation of the Dutch society for neuro-oncology treatment protocol

L. Bleeker*, M. C. M. Kouwenhoven, I. de Heer, B. I. Lissenberg-Witte, A. H. Gijsbers, H. J. Dubbink, J. M. Kros, J. M. M. Gijtenbeek, E. Kurt, C. C. D. van der Rijt, A. T. Swaak-Kragten, F. Y. de Vos, H. L. van der Weide, P. J. French, M. J. van den Bent, P. Wesseling, J. E. C. Bromberg

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Purpose: Medulloblastoma is a rare tumor in adults. The objective of this nationwide, multicenter study was to evaluate the toxicity and efficacy of the Dutch treatment protocol for adult medulloblastoma patients. Methods: Adult medulloblastoma patients diagnosed between 2010 and 2018 were identified in the Dutch rare tumors registry or nationwide pathology database. Patients with intention to treat according to the national treatment protocol were included. Risk stratification was performed based on residual disease, histological subtype and extent of disease. All patients received postoperative radiotherapy [craniospinal axis 36 Gy/fossa posterior boost 19.8 Gy (14.4 Gy in case of metastases)]. High-risk patients received additional neoadjuvant (carboplatin-etoposide), concomitant (vincristine) and adjuvant chemotherapy (carboplatin-vincristine-cyclophosphamide) as far as feasible by toxicity. Methylation profiling, and additional next-generation sequencing in case of SHH-activated medulloblastomas, were performed. Results: Forty-seven medulloblastoma patients were identified, of whom 32 were treated according to the protocol. Clinical information and tumor material was available for 28 and 20 patients, respectively. The histological variants were mainly classic (43%) and desmoplastic medulloblastoma (36%). Sixteen patients (57%) were considered standard-risk and 60% were SHH-activated medulloblastomas. Considerable treatment reductions and delays in treatment occurred due to especially hematological and neurotoxicity. Only one high-risk patient could complete all chemotherapy courses. 5-years progression-free survival (PFS) and overall survival (OS) for standard-risk patients appeared worse than for high-risk patients (PFS 69% vs. 90%, OS 81% vs. 90% respectively), although this wasn’t statistically significant. Conclusion: Combined chemo-radiotherapy is a toxic regimen for adult medulloblastoma patients that may result in improved survival.
Original languageEnglish
Pages (from-to)225-235
Number of pages11
JournalJournal of Neuro-Oncology
Issue number1
Early online date2023
Publication statusPublished - Mar 2023

Cite this